Answers are grounded in this paper and cite their sources.
Fertility preservation is increasingly relevant for reproductive-aged patients with endometrial or ovarian cancer, but oncological safety must remain the primary objective. This review summarizes current oncological and reproductive outcomes, identifies limitations in the evidence, and evaluates emerging approaches. Methods: In this structured narrative review, PubMed/MEDLINE, Scopus, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched for relevant records published through 15 August 2026. Priority was given to randomized trials, prospective cohorts, systematic reviews and meta-analyses, large registry studies, and international guidelines. Results: For atypical endometrial hyperplasia/endometrial intraepithelial neoplasia and carefully selected grade 1, stage IA endometrioid carcinoma without myometrial invasion, progestin-based treatment achieves complete response in approximately three-quarters of patients, although recurrence affects about one-third of responders. Hysteroscopic resection followed by progestin therapy may improve response and recurrence outcomes in focal disease, but comparative evidence is heterogeneous and largely non-randomized. In ovarian tumors, fertility-sparing surgery is standard for borderline tumors without invasive implants and malignant germ cell tumors and may be considered for selected early-stage epithelial and sex cord–stromal tumors after histotype-specific staging. Oocyte and embryo cryopreservation are established options when treatment threatens ovarian reserve; ovarian tissue cryopreservation and in vitro maturation have more selective indications. Molecular classification may refine counseling, whereas circulating tumor DNA, artificial-ovary platforms, in vitro follicle development, and uterus transplantation remain investigational. Conclusions: Fertility-preserving management can be oncologically acceptable with rigorous selection, multidisciplinary counseling, protocolized surveillance, and timely definitive treatment when indicated. Prospective, molecularly stratified studies with standardized oncological and reproductive outcomes are needed.
No takes yet. Share an insight, caveat, or question.
Ferrero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: